Indoleamine 2,3-dioxygenase, by degrading L-tryptophan, enhances carnitine palmitoyltransferase I activity and fatty acid oxidation, and exerts fatty acid-dependent effects in human alloreactive CD4+ T-cells
- Authors:
- Published online on: September 23, 2016 https://doi.org/10.3892/ijmm.2016.2750
- Pages: 1605-1613
Abstract
Introduction
Indoleamine 2,3-dioxygenase (IDO) is expressed in antigen-presenting cells (APCs) and has an immunoregulatory role in various models of autoimmunity and allotransplantation (1–6). In addition to APCs, IDO is expressed in trophoblast cells contributing to successful semi-allogenic pregnancy (7,8), while its expression in certain cancer cells has been incriminated for escape of cancer from immunosurveillance (9). In hemodialysis patients, who are characterized by impaired adaptive immunity, increased serum IDO levels have been associated with decreased T-cell count, as well as failure to respond to a vaccine with a T-cell dependent antigen (10,11).
By degrading L-tryptophan along the kynurenine pathway, IDO alters the local microenvironment in a manner that suppresses T-cell function. More precisely, L-tryptophan depletion activates general control non-derepressible 2 kinase (GCN2K), which phosphorylates eukaryotic initiation factor 2α (eIF2α), altering the translational program of T-cells (12–16). The effect of L-tryptophan depletion on the other amino acid sensing system, the mammalian target of rapamycin complex 1 (mTORC1), has also been investigated although with contradictory results (12–17). Kynurenine, a product of L-tryptophan degradation by IDO, by activating the aryl-hydrocarbon receptor (AhR) is involved in the immunosuppressive action of this enzyme favoring CD4+ T-cell differentiation towards regulatory T-cells (Treg) (18,19).
Considering the above described pathways as a starting point, the presence of IDO in APCs leads to decreased proliferation and increased apoptosis, and promotes the differentiation of CD4+ T-cells towards a regulatory instead of effector (Teff) phenotype (20,21). While many intermediate events remain to be elucidated, recent research indicates that IDO may exert these effects by affecting the metabolism of CD4+ T-cells. Indeed, IDO suppresses aerobic glycolysis and glutaminolysis in human alloreactive CD4+ T-cells by affecting the expression of glucose transporter 1 and various glycolytic and glutaminolytic enzymes (14–16). It also downregulates key enzymes involved in fatty acid synthesis (17). The above-mentioned metabolic pathways are prerequisites for rapid T-cell proliferation following T-cell receptor stimulation, as well as for differentiation towards effector cell lineages instead of Treg. Following T-cell activation, T-cells reprogram their metabolic pathways from pyruvate via the Krebs cycle to the glycolytic and glutaminolytic pathways in order to fulfill the bioenergetic and biosynthetic demands of proliferation (22–24). In parallel, fatty acid synthesis is upregulated during the activation of CD4+ T-cells enhancing their proliferation and promoting their differentiation into T helper 17 cells (Th17) instead of Tregs (25).
Another metabolic pathway that plays a significant role in the CD4+ T-cell response and differentiation is fatty acid β-oxidation. More precisely, Tregs are dependent on fatty acid oxidation for its differentiation, whereas, Teff populations on aerobic glycolysis (26). The effect of IDO on fatty acid oxidation in CD4+ T-cells remains to be investigated, and constitutes the aim of the present study.
For the purposes of the present study, two-way mixed lymphocyte reaction (MLR) was used as a model of alloreactivity (27), along with the specific IDO inhibitor, 1-DL- methyl-tryptophan (1MT) (4,7). In order to evaluate fatty acid oxidation, cells were cultured in a medium containing oleate. The effect of IDO on carnitine palmitoyltransferase I (CPT1), the tightly regulated enzyme that controls the entry of fatty acids into the mitochondria for oxidation (28,29), was assessed as well. Treatment of CD4+ T-cells with the CPT1 inhibitor, etomoxir, has been shown to abrogate differentiation into Tregs (26). The effects of IDO on the end-points of CD4+ T-cell function, proliferation, apoptosis and differentiation were also evaluated.
Materials and methods
Subjects
Blood samples were collected from 5 healthy volunteers (3 males and 2 females, 37±7 years of age). Informed consent was obtained from each individual enrolled in the study and the Ethics Committee of the University Hospital of Larissa (Larissa, Greece) approved the study protocol.
Cell culture conditions
Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood by the Ficoll-Hypaque density gradient centrifugation (Histopaque 1077; Sigma-Aldrich, St. Louis, MO, USA) and counted using an optical microscope (Axiovert 40 C; Carl Zeiss AG, Oberkochen, Germany) on a Neubauer plaque. Cell viability was assessed by trypan blue assay (Sigma-Aldrich). Cell cultures were performed in RPMI-1640 medium with L-glutamine, 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) and supplemented with 10% fetal bovine serum and antibiotic-antimycotic solution (both from Sigma-Aldrich). The cultures were performed at 37°C in a humidified atmosphere containing 5% CO2.
Ten MLRs were performed in the presence or absence of the IDO inhibitor 1MT (Sigma-Aldrich) at a concentration of 100 μM. The above concentration was chosen according to previous experiments that revealed efficacy without toxicity (13–16). Unless otherwise stated, in all the experiments, oleate (Sigma-Aldrich) at a final concentration of 1 mM was added from the beginning of the MLRs.
To determine cell proliferation, 10 MLRs were performed in 96-well plates for 7 days. Peripheral blood mononuclear cells from each member of the MLR couple were 5×104, measuring to 1×105 PBMCs in total in each well. Cultures of 1×105/well resting PMBCs from each member of the MLR couple were used as controls.
To assess various components in the supernatant, as well as the expression of certain proteins and CPT1 activity in CD4+ T-cells, 10 MLRs were performed in 12-well plates for 7 days. The number of PBMCs for each member of the MLR couple was 5×105, reaching a total of 1×106 PBMCs in each well. At the end of the 7-day period supernatants were collected and stored at −80°C, whereas CD4+ T-cells were isolated from the MLRs by negative selection using the CD4+ T-cell isolation kit, human (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany).
Cell proliferation in two-way mixed lymphocyte reactions
Cell proliferation enzyme-linked immunosorbent assay (ELISA) (Roche Diagnostics, Indianapolis, IN, USA), based on bromodeoxyuridine (BrdU) labeling and immunoenzymatic detection, was used to examine cell proliferation. The proliferation index was calculated as the ratio of the optical density (OD) derived from each MLR to the mean of the ODs derived from the control resting PBMC cultures of the two subjects that constituted the specific MLR. These experiments were performed in triplicate and the results refer to the mean of the three measurements.
L-tryptophan and oleate consumption in MLRs
L-tryptophan consumption was assessed by measuring its concentration in the supernatants of MLRs by means of ELISA (BlueGene Biotech, Shanghai, China). The sensitivity of the above ELISA kit is 1 ng/ml.
Similarly, oleate consumption was assessed by measuring its concentration in the supernatants of MLRs colorimetrically using the Free Fatty Acid Quantification kit (Abcam, Cambridge, UK). The detection limit of the above kit was 2 μM.
Expression of certain proteins in CD4+ T-cells isolated from the MLRs
The expression of certain proteins in CD4+ T-cells was assessed by western blot analysis. Isolated CD4+ T-cells were counted via optical microscopy on a Neubauer plaque and cell viability was determined by trypan blue assay (Sigma-Aldrich). Equal numbers of T-cells from each MLR were lysed using the T-PER tissue protein extraction reagent (Thermo Fisher Scientific Inc., Rockford, IL, USA) supplemented with protease and phosphatase inhibitors (Sigma-Aldrich and Roche Diagnostics). Protein was quantified using the Bradford assay (Sigma-Aldrich) and 10 μg from each sample were used for western blot analysis. The blots were incubated with the primary antibodies for 16 h, followed by the secondary antibody (anti-rabbit IgG, HRP-linked antibody; Cell Signaling Technology, Danvers, MA, USA) incubation for 30 min. In case of reprobing PVDF blots, the previous primary and secondary antibodies were removed using the Restore Western Blot Stripping Buffer (Thermo Fisher Scientific Inc.) according to the manufacturer's protocol. The PVDF blot was then reused and western blot analysis resumed as previously described, using a different primary antibody. Analysis of the western blots was performed using the ImageJ software (National Institute of Health, Bethesda, MD, USA).
The primary antibodies used in western blot analysis were specific for eIF2α phosphorylated at serine 51 (p-eIF2α; Cat. no. 9721) (Cell Signaling Technology), cytochrome P450, family 1, subfamily A, polypeptide 1 (CYP1A1; Cat. no. sc-20772) (Santa Cruz Biotechnology, Inc., Dallas, TX, USA), p-70S6 kinase phosphorylated at threonine 389 (p-p70S6K; Cat. no. 9234) (Cell Signaling Technology), CPT1A (Cat. no. 12252S; Cell Signaling Technology), CPT1B (Cat. no. ab134988), CPT1C (Cat. no. ab87498) (both from Abcam), acetyl-CoA carboxylase 2 (ACC2; Cat. no. 8578) (Cell Signaling Technology), ACC2 phosphorylated at serine 221 (p-ACC2; Cat. no. ab109540) (Abcam), activated cleaved at aspartate 175 caspase-3 (Cat. no. 9664), forkhead box P3 (FoxP3; Cat. no. 5298) (both from Cell Signaling Technology), retinoic acid receptor related orphan receptor γt (RORγt; Cat. no. orb6888) (Biorbyt, Cambridge, UK) and β-actin (Cat. no. 4967; Cell Signaling Technology).
Carnitine palmitoyltransferase I activity
To determine CPT1 enzyme activity, a non-radioactive method was performed in whole cell lysates according to the method of Bieber and Fiol (30). CD4+ T-cell lysates were prepared as described for western blot analysis and the method was based on measurement of the initial release of CoA-SH from palmitoyl CoA specrtrophotometrically using the reagent 5,5′-dithio-bis-(2-nitrobenzoic acid) (DTNB). Briefly, 50 μl buffer solution (containing 116 mM Tris, 2.5 mM EDTA, 2 mM DTNB, 0.2% Triton X-100, pH 8.0) and 50 μg protein extract were added to the reaction mixture. After 5 min preincubation at 28°C, 50 μl of 1 mM palmitoyl-CoA was added and the reaction was initiated with a final addition of 5 μl of 1.2 mM L-carnitine solution, followed by an immediate photometric measurement at 412 nm. These reagents were purchased from Sigma-Aldrich.
Statistical analysis
The normality of the evaluated variables was assessed and confirmed by the one-sample Kolmogorov-Smirnov test. For comparison of means the paired-sample t-test or unpaired-sample t-test were used. Results were presented as the means ± standard deviation (SD). A value of P<0.05 was considered to indicate a statistically significant difference.
The results obtained from the western blot analysis and enzyme activity assay are expressed as optical densities (OD), thus p-values were calculated by comparing the means of OD. Statistical analysis after normalization for the control OD values was avoided to prevent violation of the prerequisite for normal distribution of the compared variables when applying parametric statistical tests. However, for the reader's convenience, in the text and figures the results are noted and depicted after normalization of means for the control group.
Results
IDO increases L-tryptophan degradation in MLRs, enhances eIF2α phosphorylation and CYP1A1 expression in MLR-derived CD4+ T-cells, but does not affect p70S6K phosphorylation in MLR-derived CD4+ T-cells
In MLRs, IDO increased L-tryptophan degradation since its inhibitor 1MT increased L-tryptophan concentration in the supernatants from 2.47±0.44 to 6.19±0.47 μg/ml (p<0.001, paired t-test) (Fig. 1A).
By degrading L-tryptophan, IDO enhanced the p-eIF2α level in MLR-derived CD4+ T-cells since the treatment of MLRs with 1MT altered the p-eIF2α level by a factor of 0.52±0.18 (p<0.001, paired t-test) (Fig. 1B and C). Similarly, in CD4+ T-cells derived from 1MT-treated MLRs, CYP1A1 expression was altered by a factor of 0.51±0.29 (p<0.001, paired t-test) indicating that IDO increases CYP1A1 expression (Fig. 1B and D). By contrast, 1MT treatment of the MLRs did not affect the content of p-p70S6K in CD4+ T-cells, since its level was altered only by a factor of 1.07±0.16 (p=0.316, paired t-test) (Fig. 1B and E).
IDO increases fatty acid oxidation in MLRs and CPT1 enzymatic activity in MLR-derived CD4+ T-cells
In MLRs, IDO increased fatty acid oxidation since its inhibitor 1MT increased the oleate concentration in the supernatants from 0.51±0.05 mM to 0.82±0.03 mM (p<0.001, paired t-test) (Fig. 2A).
In CD4+ T-cells derived from 1MT-treated MLRs CPT1 activity was at the 56.61±7.32% of the activity found in cells derived from the control MLRs (p<0.001, paired t-test), indicating that IDO enhanced CPT1 enzymatic activity in CD4+ T-cells (Fig. 2B).
IDO increases CPT1A, CPT1B and CPT1C expression in MLR-derived CD4+ T-cells
Unblocked IDO activity in MLRs increased CPT1A expression in MLR-derived CD4+ T-cells since the treatment of MLRs with the IDO inhibitor, 1MT, altered the CPT1A level by a factor of 0.74±0.05 (p<0.001, paired t-test) (Fig. 3A and B). This was even more profound in the case of CPT1B, which was altered due to 1MT by a factor of 0.57±0.13 (p<0.001, paired t-test) (Fig. 3A and C), and of CPT1C, which was altered by a factor of 0.44±0.13 (p<0.001, paired t-test) (Fig. 3A and D).
IDO decreases ACC2 expression, whereas it increases the level of phosphorylated ACC2 in MLR-derived CD4+ T-cells
IDO activity in the MLRs decreased the total ACC2 expression in MLR-derived CD4+ T-cells since the treatment of MLRs with the IDO inhibitor, 1MT, led to alterations in the levels of ACC2 by a factor of 1.24±0.18 (p=0.001, paired t-test) (Fig. 4A and B).
The effect of IDO on the level of p-ACC2 was more profound since in the CD4+ T-cells derived from the 1MT-treated MLRs, the level of p-ACC2 was altered by a factor of 0.37±0.18 (p<0.001, paired t-test) (Fig. 4A and C). Thus, IDO, by degrading L-tryptophan in the MLRs, increased the content of the inactivated phosphorylated form of ACC2 in CD4+ T-cells.
IDO does not affect cell proliferation in MLRs nor activated caspase-3 in MLR-derived CD4+ T-cells
Using culture media containing oleate, IDO did not affect cell proliferation in MLRs, since the addition of 1MT did not affect the proliferation index significantly. More precisely, the proliferation index was 4.87±0.27 in the untreated MLRs and 4.75±0.34 in the 1MT-treated MLRs (p=0.313, paired t-test) (Fig. 5A).
Similarly, in the presence of oleate, IDO did not affect the content of activated caspase-3 in CD4+ T-cells, which is the terminal caspase of the apoptotic pathways. Compared to the activated caspase-3 level in CD4+ T-cells derived from the control MLRs, its level did show a negligible variation only by a factor of 0.98±0.11 in CD4+ T-cells derived from 1MT-treated MLRs (p=0.523, paired t-test) (Fig. 5B and C).
IDO, particularly in the presence of oleate, induces FoxP3 expression, but suppresses RORγt expression in MLR-derived CD4+ T-cells
Unblocked IDO activity in MLRs increased FoxP3 expression in MLR-derived CD4+ T-cells as the treatment of MLRs with the IDO inhibitor, 1MT, altered the FoxP3 level by a factor of 0.33±0.21 (p<0.001, paired t-test) (Fig. 6A and B).
The opposite was observed with the expression of RORγt. Treatment of the MLRs with the IDO inhibitor, 1MT, induced a significant increase in RORγt levels by a factor of 2.24±0.41 (p<0.001, paired t-test) (Fig. 6A and C). Thus, by degrading L-tryptophan, IDO decreased RORγt expression in CD4+ T-cells.
In the absence of oleate, treatment of the MLRs with 1MT also resulted in a decrease in FoxP3 expression in CD4+ T-cells by a factor of 0.59±0.11 (p<0.001) (Fig. 6D and E). However, this decrease was significantly less than that observed in MLRs in the presence of oleate (p=0.003, unpaired t-test) suggesting that oleate is beneficial for FoxP3 expression.
In the absence of oleate from the MLRs, 1MT treatment also resulted in an increase in RORγt expression in CD4+ T-cells by a factor of 2.11±1.28 (p<0.001) (Fig. 6D and F). This increase did not differ from the increase observed in MLRs performed in the presence of oleate (p=0.772, unpaired t-test).
Discussion
Indoleamine 2,3-dioxygenase is expressed in APCs and by degrading L-tryptophan in the microenvironment where the immune response occurs, it suppresses CD4+ T-cell function by inhibiting cell proliferation, inducing apoptosis and promoting differentiation into Tregs (20,21).
In order to define which of the described pathways are involved in the effect of IDO on CD4+ T cells (12–14,17–19), a model of alloreactivity, the MLR, was used. In this model, IDO induced L-tryptophan degradation. Decreased L-tryptophan activated the GCN2K pathway since the phosphorylation of its substrate eIF2α was increased when IDO activity was not blocked by 1MT. This observation is in accordance with previous studies (12–14). Additionally, the present study recapitulates the results of other studies that failed to detect an effect on the other amino-acid sensing system, the mTORC1, since the level of phosphorylation of its substrate, p70S6K, remained unaffected by 1MT (12–14). This is in accordance with findings showing that mTORC1 is sensitive to the depletion of certain amino acids; and more precisely of leucine, isoleucine, valine and possibly arginine, but not of tryptophan (31). Furthermore, L-tryptophan depletion and its degradation by IDO results in the production of kynurenine, which may affect CD4+ T-cell function (18,19). In the MLR-derived CD4+ T cells, the expression of CYP1A1, a transcriptional target of AhR, was increased in the absence of 1MT, indicating that the IDO kynurenine AhR pathway is associated with our experimental model.
Recent studies have confirmed that IDO may exert its effect on CD4+ T cells by affecting their metabolism (13–16). Specifically, L-tryptophan degradation by IDO has been shown to decrease aerobic glycolysis, glutaminolysis and fatty acid synthesis (13–16), all required for rapid CD4+ T-cell proliferation and differentiation towards Teff lineages (22–25). The results of the present study confirmed that L-tryptophan degradation by IDO increased fatty acid consumption in MLRs. In parallel, the activity of CPT1 in MLR-derived CD4+ T cells increased. Fatty acid β-oxidation occurs in the mitochondrial matrix. However, acyl-CoAs cannot pass the inner mitochondrial membrane, unless they are converted to acylcarnitine in the cytoplasmic surface of the inner mitochondrial membrane. This reaction is catalyzed by CPT1, which, by controlling the entry of fatty acid into the mitochondrial matrix regulates the rate of fatty acid oxidation (28,29).
The reason for the increased CPT1 activity in CD4+ T cells derived from MLR without the IDO inhibitor, 1MT, may be due to the increased levels of the three CPT1 isoenzymes identified in the current study. A possible explanation may depend on the confirmed effect of IDO-induced L-tryptophan degradation in transcription factors such as p53 and cMyc that control cell metabolism in CD4+ T cells (14,16). However, the exact mechanism for this IDO-related increase in CPT1A, CPT1B and CPT1C expression remains to be elucidated.
In addition to CPT1 expression, the activity of this enzyme is tightly regulated and more precisely, is allosterically inhibited by malonyl-CoA. Malonyl-CoA is produced by ACC2, an enzyme associated with the outer mitochondrial membrane (28,29). When IDO activity was not inhibited in MLRs, ACC2 expression in the MLR-derived CD4+ T cells decreased. In addition, possibly due to AMP-activated protein kinase (AMPK) (32), the phosphorylated inactivated form of ACC2 increased markedly. This IDO-induced alteration in ACC2 is expected to lead to decreased ACC2 activity, decreased malonyl-CoA production and increased CPT1 activity and fatty acid β-oxidation.
We also evaluated the effect of IDO-induced L-tryptophan degradation on two terminal points of CD4+ T-cell immune response, proliferation and apoptosis. Contrary to what has been shown in a similar experimental model (13–16), IDO did not affect cell proliferation in MLRs, or CD4+ T-cell apoptosis as assessed by activated caspase-3, the terminal caspase at which all the apoptotic pathways converge (33). However, the presence of oleate in the culture medium in the present study yielded different results. Oleate, as a fatty acid, along with the IDO-induced increase in fatty acid oxidation may protect CD4+ T-cells from energy deprivation, since IDO is known to decrease glucose influx in the cell, aerobic glycolysis and glutaminolysis (13–16). The presence of a fatty acid in the culture medium may protect cells from energy deprivation, thus also preventing the inhibition of cell proliferation and the induction of apoptosis. These results also raise the question of whether it is more appropriate to perform immunological experiments using more 'normal' culture medium, which contains fatty acids.
The effect of IDO-induced L-tryptophan degradation on the expression of the Treg signature transcription factor FoxP3, and of the Th17 signature transcription factor, RORγt, was evaluated (34). The two CD4+ T-cell lineages are formed reciprocally as regards fatty acid metabolism. Fatty acid synthesis favors differentiation into the Th17 lineage, whereas fatty acid oxidation favors differentiation into Tregs (25,26). According to what is generally considered (35–37), IDO increased FoxP3, but decreased RORγt expression in MLR-derived CD4+ T-cells. In order to define the effect of the presence of fatty acid in the culture medium, we repeated the experiments without oleate. No difference was detected s regards RORγt; however, the presence of oleate IDO induced a greater increase in FoxP3 expression. The reason remains to be defined, since various aspects regarding the mechanisms that connect fatty acid metabolism with CD4+ T-cell function, such as post-translational protein modification by lipids or the availability of acetyl-CoA for epigenetic modifications, are under investigation (38). Thus, this raises the question of whether a culture medium containing fatty acids more closely mimics the in vivo conditions and may thus be more suitable for lymphocyte culture studies.
In conclusion, the present study demonstrated that IDO, by degrading L-tryptophan, enhanced CPT1 activity and fatty acid oxidation, and exerted fatty acid-dependent effects in human alloreactive CD4+ T cells.
References
|
Seo SK, Choi JH, Kim YH, Kang WJ, Park HY, Suh JH, Choi BK, Vinay DS and Kwon BS: 4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat Med. 10:1088–1094. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Gurtner GJ, Newberry RD, Schloemann SR, McDonald KG and Stenson WF: Inhibition of indoleamine 2,3-dioxygenase augments trinitrobenzene sulfonic acid colitis in mice. Gastroenterology. 125:1762–1773. 2003. View Article : Google Scholar | |
|
Kwidzinski E, Bunse J, Aktas O, Richter D, Mutlu L, Zipp F, Nitsch R and Bechmann I: Indolamine 2,3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation. FASEB J. 19:1347–1349. 2005.PubMed/NCBI | |
|
Alexander AM, Crawford M, Bertera S, Rudert WA, Takikawa O, Robbins PD and Trucco M: Indoleamine 2,3-dioxygenase expression in transplanted NOD Islets prolongs graft survival after adoptive transfer of diabetogenic splenocytes. Diabetes. 51:356–365. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Beutelspacher SC, Pillai R, Watson MP, Tan PH, Tsang J, McClure MO, George AJ and Larkin DF: Function of indoleamine 2,3-dioxygenase in corneal allograft rejection and prolongation of allograft survival by over-expression. Eur J Immunol. 36:690–700. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Li Y, Tredget EE, Ghaffari A, Lin X, Kilani RT and Ghahary A: Local expression of indoleamine 2,3-dioxygenase protects engraftment of xenogeneic skin substitute. J Invest Dermatol. 126:128–136. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, Brown C and Mellor AL: Prevention of allogeneic fetal rejection by tryptophan catabolism. Science. 281:1191–1193. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Mellor AL, Sivakumar J, Chandler P, Smith K, Molina H, Mao D and Munn DH: Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy. Nat Immunol. 2:64–68. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Munn DH and Mellor AL: Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest. 117:1147–1154. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Eleftheriadis T, Yiannaki E, Antoniadi G, Liakopoulos V, Pissas G, Galaktidou G and Stefanidis I: Plasma indoleamine 2,3-dioxygenase and arginase type I may contribute to decreased blood T-cell count in hemodialysis patients. Ren Fail. 34:1118–1122. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Eleftheriadis T, Liakopoulos V, Antoniadi G, Stefanidis I and Galaktidou G: Indoleamine 2,3-dioxygenase is increased in hemodialysis patients and affects immune response to hepatitis B vaccination. Vaccine. 29:2242–2247. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Munn DH, Sharma MD, Baban B, Harding HP, Zhang Y, Ron D and Mellor AL: GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity. 22:633–642. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Eleftheriadis T, Pissas G, Antoniadi G, Liakopoulos V and Stefanidis I: Indoleamine 2,3-dioxygenase depletes tryptophan, activates general control non-derepressible 2 kinase and down-regulates key enzymes involved in fatty acid synthesis in primary human CD4+ T cells. Immunology. 146:292–300. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Eleftheriadis T, Pissas G, Antoniadi G, Spanoulis A, Liakopoulos V and Stefanidis I: Indoleamine 2,3-dioxygenase increases p53 levels in alloreactive human T cells, and both indoleamine 2,3-dioxygenase and p53 suppress glucose uptake, glycolysis and proliferation. Int Immunol. 26:673–684. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Eleftheriadis T, Pissas G, Yiannaki E, Markala D, Arampatzis S, Antoniadi G, Liakopoulos V and Stefanidis I: Inhibition of indoleamine 2,3-dioxygenase in mixed lymphocyte reaction affects glucose influx and enzymes involved in aerobic glycolysis and glutaminolysis in alloreactive T-cells. Hum Immunol. 74:1501–1509. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Eleftheriadis T, Pissas G, Antoniadi G, Tsogka K, Sounidaki M, Liakopoulos V and Stefanidis I: Indoleamine 2,3 dioxygenase downregulates T cell receptor complex ζ chain and c Myc, and reduces proliferation, lactate dehydrogenase levels and mitochondrial glutaminase in human T cells. Mol Med Rep. 13:925–932. 2016. | |
|
Cobbold SP, Adams E, Farquhar CA, Nolan KF, Howie D, Lui KO, Fairchild PJ, Mellor AL, Ron D and Waldmann H: Infectious tolerance via the consumption of essential amino acids and mTOR signaling. Proc Natl Acad Sci USA. 106:12055–12060. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ and Bradfield CA: An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol. 185:3190–3198. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, Schumacher T, Jestaedt L, Schrenk D, Weller M, et al: An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature. 478:197–203. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
King NJ and Thomas SR: Molecules in focus: Indoleamine 2,3-dioxygenase. Int J Biochem Cell Biol. 39:2167–2172. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Curti A, Trabanelli S, Salvestrini V, Baccarani M and Lemoli RM: The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: Focus on hematology. Blood. 113:2394–2401. 2009. View Article : Google Scholar | |
|
Maciver NJ, Jacobs SR, Wieman HL, Wofford JA, Coloff JL and Rathmell JC: Glucose metabolism in lymphocytes is a regulated process with significant effects on immune cell function and survival. J Leukoc Biol. 84:949–957. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Fox CJ, Hammerman PS and Thompson CB: Fuel feeds function: Energy metabolism and the T-cell response. Nat Rev Immunol. 5:844–852. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Wang R, Dillon CP, Shi LZ, Milasta S, Carter R, Finkelstein D, McCormick LL, Fitzgerald P, Chi H, Munger J, et al: The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity. 35:871–882. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Berod L, Friedrich C, Nandan A, Freitag J, Hagemann S, Harmrolfs K, Sandouk A, Hesse C, Castro CN, Bähre H, et al: De novo fatty acid synthesis controls the fate between regulatory T and T helper 17 cells. Nat Med. 20:1327–1333. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Michalek RD, Gerriets VA, Jacobs SR, Macintyre AN, MacIver NJ, Mason EF, Sullivan SA, Nichols AG and Rathmell JC: Cutting edge: Distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J Immunol. 186:3299–3303. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Sato T, Deiwick A, Raddatz G, Koyama K and Schlitt HJ: Interactions of allogeneic human mononuclear cells in the two-way mixed leucocyte culture (MLC): Influence of cell numbers, subpopulations and cyclosporin. Clin Exp Immunol. 115:301–308. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS and Stanley WC: Myocardial fatty acid metabolism in health and disease. Physiol Rev. 90:207–258. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Schreurs M, Kuipers F and van der Leij FR: Regulatory enzymes of mitochondrial beta-oxidation as targets for treatment of the metabolic syndrome. Obes Rev. 11:380–388. 2010. View Article : Google Scholar | |
|
Bieber LL and Fiol C: Purification and assay of carnitine acyltransferases. Methods Enzymol. 123:276–284. 1986. View Article : Google Scholar : PubMed/NCBI | |
|
Gallinetti J, Harputlugil E and Mitchell JR: Amino acid sensing in dietary-restriction-mediated longevity: Roles of signal-transducing kinases GCN2 and TOR. Biochem J. 449:1–10. 2013. View Article : Google Scholar : | |
|
Mihaylova MM and Shaw RJ: The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol. 13:1016–1023. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Fadeel B and Orrenius S: Apoptosis: A basic biological phenomenon with wide-ranging implications in human disease. J Intern Med. 258:479–517. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Raphael I, Nalawade S, Eagar TN and Forsthuber TG: T cell subsets and their signature cytokines in autoimmune and inflammatory diseases. Cytokine. 74:5–17. 2015. View Article : Google Scholar : | |
|
Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C, Orabona C, Bianchi R, Belladonna ML, Volpi C, et al: The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol. 176:6752–6761. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Sharma MD, Baban B, Chandler P, Hou DY, Singh N, Yagita H, Azuma M, Blazar BR, Mellor AL and Munn DH: Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest. 117:2570–2582. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Sharma MD, Hou DY, Liu Y, Koni PA, Metz R, Chandler P, Mellor AL, He Y and Munn DH: Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. Blood. 113:6102–6111. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Lochner M, Berod L and Sparwasser T: Fatty acid metabolism in the regulation of T cell function. Trends Immunol. 36:81–91. 2015. View Article : Google Scholar : PubMed/NCBI |
